Exact Sciences to Participate in September Investor Conferences
19 augusti, 12:00
19 augusti, 12:00
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.
The webcast can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company’s growing portfolio includes well-established brands such as Cologuard® and Oncotype DX®, along with innovative solutions like Oncodetect™ for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250819553548/en/
19 augusti, 12:00
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.
The webcast can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company’s growing portfolio includes well-established brands such as Cologuard® and Oncotype DX®, along with innovative solutions like Oncodetect™ for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250819553548/en/
Inför Nibes rapport
Analys
Aktierekommendationer
Aktier
Bostadsmarknaden
Selins sorti
Analys
Aktierekommendationer
Aktier
Bostadsmarknaden
Selins sorti
1 DAG %
Senast
OMX Stockholm 30
1 DAG %
Senast
2 646,58